IP Library Granted Patent US 10,591,474
Granted Patent B2
US 10,591,474 · App. 15/579,038 · Granted Mar 17, 2020

Point-of-care fluorescent immunoassay for identifying biomarkers in patient biofluid samples

Inventors: Benjamin Katchman (Tempe, AZ); Karen Anderson (Scottsdale, AZ); Joseph Smith (Tempe, AZ); Jennifer Blain Christen (Chandler, AZ)
Assignee: Arizona Board of Regents on behalf of Arizona State University
G01N33/54373B01L3/502715G01N21/6428G01N33/54386G01N33/58G01N33/582G01N33/6857G01N2333/025
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,591,474
App. No.
15/579,038
Granted
Mar 17, 2020
Kind
B2
Abstract

Systems and methods for low-cost point-of-care immunoassay are provided. The system comprises an emitter, two optical interference filters, a microscope slide, a photodiode detector, a circuit, and a measuring unit. The detector is placed upon the second filter, the slide, the first filter, and then the emitter. The emitter comprises non-organic light emitting diodes (LEDs) or organic light emitting diodes (OLEDs) that emits light of a first color. The slide is spotted with biofluid from a patient. Biomarkers in the biofluid is bound with immobilized fluorophores that emit light of a second color when stimulated by the light of the first color. The first and second filters band-pass the light of the first and second colors, respectively. The detector detects light of the second color. The current outputted from the detector is converted into a relatively-large output voltage by a circuit. A measuring unit measures the ramp time of the output voltage. The ramp time is to be used to determine the concentration of the fluorophores, which in turn is related to the concentration of the biomarkers.

Claims (24)

1. A system for low-cost point-of-care immunoassay, comprising:

a) an emitter comprising non-organic light emitting diodes (LEDs) or organic light emitting diodes (OLED) that emits light of a first color when pulsed with electrical current;

b) a first optical interference filter that band-passes the light of the first color;

c) a substrate comprising one or more protein biomarkers of interest to which biofluid from a patient is contacted, wherein, when the biofluid comprises an analyte that binds to protein biomarkers of interest, the analyte immobilizes fluorophores to the one or more protein biomarkers whereby the fluorophores and emit light of a second color when stimulated by the light of the first color;

d) a second optical interference filter that band-passes the light of the second color;

e) a photodiode detector that detects the light of the second color, wherein the detector is placed upon the second filter, the substrate, the first filter, and then the emitter;

f) an op-amp charge integration circuit that converts current outputted from the photodiode detector into an output voltage; and

g) a measuring unit that measures a ramp time of the output voltage, wherein the ramp time is used to determine a concentration of the fluorophores related to a concentration of the biomarkers.

2. The system as recited in claim 1 , further comprising a 3D printed assembly configured to align a center of the substrate with the first filter and the second filter.

3. The system as recited in claim 1 , wherein the substrate in c) is prepared by procedures comprising:

i) depositing proteins onto the substrate;

ii) incubating the proteins with the biofluid; and

iii) incubating the proteins further with fluorophore-labeled detection antibodies associated with the protein biomarkers.

4. The system as recited in claim 3 , wherein step ii) is repeated one or more times to achieve a desired sensitivity.

5. The system of claim 3 , wherein the procedures further comprise a first step of silanizing the substrate.

6. The system as recited in claim 1 , wherein the ramp time is a time interval that the output voltage takes to ramp from 0 volt to a supply voltage rail.

7. The system as recited in claim 1 , wherein the ramp time is a time interval that the output voltage takes to ramp from a first voltage to a second voltage.

8. The system as recited in claim 1 , wherein the first filter is deposited in the emitter.

9. The system as recited in claim 1 , wherein the biofluid is serum.

10. The system as recited in claim 9 , wherein the biomarkers are for papillomavirus.

11. The system as recited in claim 1 , wherein the biomarkers are antibodies specific for HPV16 E7.

12. The system as recited in claim 1 , wherein the substrate is a microscope slide.

13. The system of claim 1 , wherein the op-amp charge integration circuit converts current to the output voltage using an op-charge integration time of at least 10 seconds.

14. The system of claim 1 , wherein the op-amp charge integration circuit converts current to the output voltage using an op-charge integration time of about 30 seconds to about 60 seconds.

Assignments (3)
CONFIRMATORY LICENSE Recorded Dec 7, 2022
From: ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 062080/0400 →
CONFIRMATORY LICENSE Recorded Oct 21, 2020
From: ARIZONA STATE UNIVERSITY, TEMPE
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 054167/0763 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2018
From: KATCHMAN, BENJAMIN; ANDERSON, KAREN; SMITH, JOSEPH; BLAIN CHRISTEN, JENNIFER M.
To: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
Reel/Frame 045299/0348 →
Continuity (2)
Provisional Application 62170638 · Jun 3, 2015
Related Publication 20180172681A1 · Jun 21, 2018
Cited By (1)
US 12,661,655